News

Misperceptions and a focus on weight-loss medications risk oversimplifying a complex health crisis. Read more at straitstimes ...
Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...
Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...
A decision is expected in the fourth quarter of 2025.
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...